Skip to content
The Policy VaultThe Policy Vault

Haegarda (C1 esterase inhibitor Subcutaneous, human)United Healthcare

routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks

Initial criteria

  • Diagnosis of hereditary angioedema (HAE)
  • For prophylaxis against HAE attacks
  • Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Takhzyro, Orladeyo)
  • age ≥ 6 years

Approval duration

12 months